The Food and Drug Administration last week authorized the emergency use of a third diagnostic test that detects and differentiates flu and COVID-19 viruses from one another. 

The test from the Centers for Disease Control and Prevention, along with previously authorized tests from BioFire Diagnostics LLC and QIAGEN GmbH, require only a single sample from patients who exhibit respiratory disease symptoms. FDA said these tests will use fewer supplies and provide faster and comprehensive results.

Related News Articles

Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…
Headline
The Centers for Disease Control and Prevention and the Department of Health and Human Services adopted Aug. 4 the Advisory Committee on Immunization Practices…
Headline
Five pediatric flu deaths were reported to the Centers for Disease Control and Prevention last week, pushing the total to 266 for the 2024-2025 flu season,…
Headline
The Department of Health and Human Services July 23 announced it is recommending the removal of thimerosal from all U.S. flu vaccines. The announcement follows…
Headline
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Centers for Disease Control and Prevention July 7 announced it is streamlining H5N1 bird flu updates with its routine influenza data given the low public…